JPWO2020069445A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020069445A5
JPWO2020069445A5 JP2021517802A JP2021517802A JPWO2020069445A5 JP WO2020069445 A5 JPWO2020069445 A5 JP WO2020069445A5 JP 2021517802 A JP2021517802 A JP 2021517802A JP 2021517802 A JP2021517802 A JP 2021517802A JP WO2020069445 A5 JPWO2020069445 A5 JP WO2020069445A5
Authority
JP
Japan
Prior art keywords
glycero
composition
phosphocholine
composition according
phosphoethanolamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021517802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502451A (ja
JP2022502451A5 (https=
JP7430713B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053661 external-priority patent/WO2020069445A1/en
Publication of JP2022502451A publication Critical patent/JP2022502451A/ja
Publication of JP2022502451A5 publication Critical patent/JP2022502451A5/ja
Publication of JPWO2020069445A5 publication Critical patent/JPWO2020069445A5/ja
Application granted granted Critical
Publication of JP7430713B2 publication Critical patent/JP7430713B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021517802A 2018-09-28 2019-09-27 核酸送達のための脂質化カチオン性ペプチド化合物を含む脂質ナノ粒子製剤 Active JP7430713B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862738717P 2018-09-28 2018-09-28
US62/738,717 2018-09-28
US201962885036P 2019-08-09 2019-08-09
US62/885,036 2019-08-09
PCT/US2019/053661 WO2020069445A1 (en) 2018-09-28 2019-09-27 Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery

Publications (4)

Publication Number Publication Date
JP2022502451A JP2022502451A (ja) 2022-01-11
JP2022502451A5 JP2022502451A5 (https=) 2022-10-05
JPWO2020069445A5 true JPWO2020069445A5 (https=) 2022-10-05
JP7430713B2 JP7430713B2 (ja) 2024-02-13

Family

ID=69952323

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517802A Active JP7430713B2 (ja) 2018-09-28 2019-09-27 核酸送達のための脂質化カチオン性ペプチド化合物を含む脂質ナノ粒子製剤
JP2021517865A Active JP7418419B2 (ja) 2018-09-28 2019-09-27 核酸送達のための第三級アミノ脂質化カチオン性ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021517865A Active JP7418419B2 (ja) 2018-09-28 2019-09-27 核酸送達のための第三級アミノ脂質化カチオン性ペプチド

Country Status (14)

Country Link
US (4) US20210322575A1 (https=)
EP (2) EP3856757A4 (https=)
JP (2) JP7430713B2 (https=)
KR (2) KR20210068092A (https=)
CN (2) CN112789031B (https=)
AU (2) AU2019347774A1 (https=)
BR (2) BR112021005815A2 (https=)
CA (2) CA3110914A1 (https=)
IL (2) IL281135B2 (https=)
MX (2) MX2021003420A (https=)
MY (1) MY204458A (https=)
SG (2) SG11202102164PA (https=)
WO (2) WO2020069442A1 (https=)
ZA (2) ZA202101376B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112789031B (zh) * 2018-09-28 2023-03-24 胡桃钳医疗公司 用于核酸递送的包含脂化的阳离子肽化合物的脂质纳米颗粒制剂
MX2022001660A (es) * 2019-08-09 2022-04-18 Nutcracker Therapeutics Inc Composiciones peg de péptidos catiónicos lipidados para la administración de ácidos nucleicos.
IL297161A (en) * 2020-04-22 2022-12-01 Nutcracker Therapeutics Inc Therapeutic mrna nanoparticles
NL2026825B1 (en) 2020-08-07 2022-04-05 Nutcracker Therapeutics Inc Multicomponent delivery system for polyanionic cargo compound delivery
US20230293706A1 (en) 2020-08-07 2023-09-21 Nutcracker Therapeutics, Inc. Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery
US20240024466A1 (en) * 2020-12-07 2024-01-25 Trustees Of Tufts College Lipidoid compositions and methods of use thereof
EP4333898A4 (en) * 2021-05-05 2026-03-25 Arcturus Therapeutics Inc PEPTIDE-LIPID CONJUGATES
US20240307526A1 (en) 2021-08-06 2024-09-19 Nutcracker Therapeutics, Inc. Compositions comprising hydroxyethyl-capped cationic peptoids
NL2029057B1 (en) 2021-08-06 2023-02-21 Nutcracker Therapeutics Inc Compositions comprising hydroxyethyl-capped cationic peptoids
CN114778712B (zh) * 2022-03-21 2023-06-02 天津键凯科技有限公司 一种聚乙二醇脂质及含有该脂质的脂质纳米粒含量的检测方法
KR20250065342A (ko) 2022-09-09 2025-05-12 넛크래커 테라퓨틱스 인코포레이티드 핵산 전달용 2-아미노프로판-1,3-다이올 캡핑된 양이온성 펩토이드
WO2025006851A1 (en) 2023-06-29 2025-01-02 Nutcracker Therapeutics, Inc. Ethyl modified rna caps and methods of use
WO2025053636A1 (ko) * 2023-09-05 2025-03-13 한국생명공학연구원 지질 나노 입자를 이용한 핵산 전달 시스템
WO2025137277A1 (en) 2023-12-19 2025-06-26 Nutcracker Therapeutics, Inc. Degradable peptoids
WO2025189064A1 (en) 2024-03-08 2025-09-12 Genzyme Corporation Lipid nanoparticles
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6191115B1 (en) * 1998-08-12 2001-02-20 Abbott Laboratories C-terminus modified heptapeptide LHRH analogs
WO2001016306A2 (en) 1999-08-27 2001-03-08 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
JP2004535388A (ja) * 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
ES2559828T3 (es) * 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
CA2549720C (en) * 2003-12-19 2013-10-15 Chiron Corporation Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
ITMI20061607A1 (it) * 2006-08-09 2008-02-10 Maria Vincenza Carriero Peptidi con attivita farmacologica
CA2689145A1 (en) 2007-06-04 2008-12-11 Pressure Biosciences Inc. Pressure-enhanced extraction and partitioning of molecules
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
WO2009132131A1 (en) * 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
HUE037082T2 (hu) 2008-11-10 2018-08-28 Arbutus Biopharma Corp Új lipidek és készítmények terápiás hatóanyagok szállítására
TW201019969A (en) * 2008-11-17 2010-06-01 Enzon Pharmaceuticals Inc Branched cationic lipids for nucleic acids delivery system
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US20110053829A1 (en) * 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
CA2816925C (en) 2009-11-04 2023-01-10 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
HUE042177T2 (hu) 2009-12-01 2019-06-28 Translate Bio Inc Szteroidszármazék mRNS szállítására humán genetikai betegségekben
US8748667B2 (en) 2010-06-04 2014-06-10 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
DK2631291T3 (da) 2010-10-22 2019-06-11 Olix Pharmaceuticals Inc Nukleinsyremolekyler, der inducerer rna-interferens, og anvendelser deraf
EP2686342A2 (en) * 2011-04-12 2014-01-22 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
WO2013148541A1 (en) 2012-03-27 2013-10-03 Merck Sharp & Dohme Corp. DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
KR101480055B1 (ko) 2012-04-04 2015-01-09 주식회사 삼양바이오팜 음이온성 약물 전달체의 제조 방법
US10245229B2 (en) 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
US20150182461A1 (en) 2012-06-19 2015-07-02 Massachussets Institute Of Technology Mass Production and Size Control of Nanoparticles Through Controlled Microvortices
TW201726600A (zh) 2012-07-06 2017-08-01 協和醱酵麒麟有限公司 陽離子性脂質
US9687448B2 (en) 2012-12-07 2017-06-27 Alnylam Pharmaceuticals, Inc. Nucleic acid lipid particle formulations
SG11201507474QA (en) 2013-03-14 2015-10-29 Shire Human Genetic Therapies RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
ES2555160B1 (es) 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
JP7105065B2 (ja) 2014-12-15 2022-07-22 ダイセルナ ファーマシューティカルズ, インコーポレイテッド リガンド修飾二本鎖核酸
SMT202100196T1 (it) 2015-07-22 2021-05-07 Nitto Denko Corp Composizioni e metodi per forme liofile di nanoparticelle
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
WO2017100154A1 (en) * 2015-12-07 2017-06-15 Purdue Research Foundation Inhibitors for proliferating cell nuclear antigen and uses
JP6457704B2 (ja) 2015-12-13 2019-01-23 日東電工株式会社 高活性及びオフターゲット削減のためのsiRNA構造
WO2018064755A1 (en) * 2016-10-03 2018-04-12 Precision Nanosystems Inc. Compositions for transfecting resistant cell types
MX2019005470A (es) 2016-11-10 2019-11-21 Translate Bio Inc Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm.
WO2018107061A1 (en) 2016-12-09 2018-06-14 Board Of Regents, The University Of Texas System Hybrid exosomal-polymeric (hexpo) nano-platform for delivery of rnai therapeutics
JP7406793B2 (ja) 2017-06-23 2023-12-28 ユニバーシティー オブ マサチューセッツ 2テイル自己デリバリー型siRNAおよび関連方法
CN112789031B (zh) * 2018-09-28 2023-03-24 胡桃钳医疗公司 用于核酸递送的包含脂化的阳离子肽化合物的脂质纳米颗粒制剂

Similar Documents

Publication Publication Date Title
JPWO2020069445A5 (https=)
JP4842821B2 (ja) ポリエチレングリコール修飾脂質化合物およびその使用
JP2021522163A5 (https=)
JPWO2020061367A5 (https=)
JP2022184875A5 (https=)
JP2021059555A5 (https=)
EP3675826B1 (en) Cationic lipid compositions for tissue-specific delivery
JP2019519568A5 (https=)
JP2019023243A5 (https=)
US20130149374A1 (en) Asymmetric Liposomes for the Highly Efficient Encapsulation of Nucleic Acids and Hydrophilic Anionic Compounds, and Method for Preparing Same
IL278079B2 (en) Inhalable liposomal sustained release composition for use in treating pulmonary diseases
CN110114058A (zh) 用于递送mrna的改进的基于ice的脂质纳米颗粒制剂
JP2011507534A5 (https=)
EP2608785B1 (en) Lipomacrocycles and uses thereof
JP2019500430A5 (https=)
JPWO2021155274A5 (https=)
JP2017536092A5 (https=)
US20240197636A1 (en) Tissue-specific nucleic acid delivery by mixed cationic lipid particles
JP2019514985A5 (https=)
JPWO2023044333A5 (https=)
JPWO2019209787A5 (https=)
JP2025501905A (ja) イオン化脂質、脂質ナノ粒子、及びこれらの使用
JP2004508012A (ja) エンドソーム膜不安定剤を用いたsplp媒介性トランスフェクションの強化方法
JP2010507580A5 (https=)
TWI760319B (zh) 乳癌治療